Tech Company Financing Transactions
Orchestra BioMed Funding Round
On 7/16/2019, Orchestra BioMed raised $34 million in Series B funding from Perceptive Advisors, RTW Investments and Soleus Capital.
Transaction Overview
Company Name
Announced On
7/16/2019
Transaction Type
Venture Equity
Amount
$34,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to accelerate and expand development of Orchestra BioMed's lead and pipeline assets, including BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Union Square Dr.
New Hope, PA 18938
USA
New Hope, PA 18938
USA
Phone
Website
Email Address
Overview
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Hochman
Chief Financial Officer
Evan Ballantyne
Chief Medical Officer
Dennis Donohoe
Chief Medical Officer
Steven Evans
Chief Operating Officer
Darren Sherman
Chief Technical Officer
Yuval Mika
VP - Marketing
Inessa Wheeler
VP - R & D
Ziv Belsky
VP - Regulatory Affairs
Eileen Bailey
VP - Regulatory Affairs
William Baumbach
Browse more venture capital transactions:
Prev: 7/16/2019: DefenseStorm venture capital transaction
Next: 7/16/2019: Recursion Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs